Actuate Therapeutics, Inc. Common stock (ACTU) Stock Forecast & Price Target
Actuate Therapeutics, Inc. Common stock · NASDAQ
$1.57+0.34 (+27.64%)
15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Actuate Therapeutics, Inc. Common stock, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $6.00 to $20.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $13.67 sits 770% above the current $1.57. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.15 next quarter toward $-0.72 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Actuate Therapeutics, Inc. Common stock.
As of Aug, 2 of 2 firms rate ACTU a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ACTU EPS & revenue forecast
EPS · NEXT QUARTER
$-0.15
Range $-0.16 – $-0.15 · 2 analysts · -14% YoY
Next period, 2 analysts expect Actuate Therapeutics, Inc. Common stock to earn $-0.15 a share (range $-0.16 – $-0.15), versus $-0.18 a year earlier. Full-year consensus is $-0.67, growing to $-0.72 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Actuate Therapeutics, Inc. Common stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACTU.
#1
Mayank Mamtani
B. Riley Securities · Rank #11
Buy
$20.00+1173.9% to target
Overall win rate
52%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #243
Buy
$15.00+855.4% to target
Overall win rate
38%
+ Follow
#3
MG
Michael G. King Jr.
Rodman & Renshaw
Buy
$6.00+282.2% to target
Coverage
—
+ Follow
#4
CL
Christopher Liu
Lucid Capital
Buy
$5.00+218.5% to target
Coverage
—
+ Follow
#5
AL
Albert Lowe
Craig-Hallum
Buy
$12.00+664.3% to target
Coverage
—
+ Follow
ACTU stock forecast FAQ
What is ACTU's average 12-month price target?+
The 3 analysts with a live target average $13.67 for Actuate Therapeutics, Inc. Common stock over the next 12 months, ranging from a $20.00 high to a $6.00 low.
Is ACTU stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ACTU?+
The Street-high target is $20.00 (B. Riley Securities), and the Street-low is $6.00 (Rodman & Renshaw). The average of all 3 active targets is $13.67.
How many Wall Street analysts cover ACTU?+
3 analysts have an active rating on Actuate Therapeutics, Inc. Common stock, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering ACTU?+
Among analysts who currently cover ACTU, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #11). Their current call is Buy with a $20.00 target.
What is Actuate Therapeutics, Inc. Common stock's projected EPS for next quarter?+
The consensus estimate is $-0.15 per share (range $-0.16 – $-0.15) across 2 analysts. Full-year EPS is projected at $-0.67, rising to $-0.72 the following year.
How much revenue is Actuate Therapeutics, Inc. Common stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ACTU lately?+
As of Aug, 2 of 2 firms rate ACTU a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACTU calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
